Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy
Primary Purpose
Pregnancy, Ectopic
Status
Completed
Phase
Phase 4
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Single
Multipe
Sponsored by
About this trial
This is an interventional treatment trial for Pregnancy, Ectopic
Eligibility Criteria
Inclusion Criteria:
- unruptured tubal EP
- gestational mass of less than or equal to 3.5 cm in ultrasonography report
Exclusion Criteria:
- hemodynamic instability
- contraindications related to the use of MTX
- hepatic
- renal and active pulmonary diseases
- peptic ulcer
- immune deficiency status
- alcohol abuse
- blood dyscreasia
Sites / Locations
- Shariaty Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Multiple dose mtx
Single Dose
Arm Description
mtx
In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
Outcomes
Primary Outcome Measures
hCG level decrease
Secondary Outcome Measures
Full Information
NCT ID
NCT01662167
First Posted
August 5, 2012
Last Updated
August 9, 2012
Sponsor
Hormozgan University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT01662167
Brief Title
Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy
Official Title
Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy: a Clinical Trail
Study Type
Interventional
2. Study Status
Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hormozgan University of Medical Sciences
4. Oversight
5. Study Description
Brief Summary
The aim of this study was to compare single dose Methotrexate (MTX) to multiple dose MTX.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Ectopic
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
87 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Multiple dose mtx
Arm Type
Experimental
Arm Description
mtx
Arm Title
Single Dose
Arm Type
Experimental
Arm Description
In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
Intervention Type
Drug
Intervention Name(s)
Single
Intervention Description
In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
Intervention Type
Drug
Intervention Name(s)
Multipe
Intervention Description
In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
Primary Outcome Measure Information:
Title
hCG level decrease
Time Frame
4 days after administration
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
unruptured tubal EP
gestational mass of less than or equal to 3.5 cm in ultrasonography report
Exclusion Criteria:
hemodynamic instability
contraindications related to the use of MTX
hepatic
renal and active pulmonary diseases
peptic ulcer
immune deficiency status
alcohol abuse
blood dyscreasia
Facility Information:
Facility Name
Shariaty Hospital
City
Bandar Abbas
State/Province
Hormozgan
ZIP/Postal Code
79761
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Learn more about this trial
Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy
We'll reach out to this number within 24 hrs